Compile Data Set for Download or QSAR
Report error Found 151 Enz. Inhib. hit(s) with all data for entry = 10741
TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562786(US11407721, Example 32 | US11407721, Example 33 | ...)
Affinity DataIC50: 39.9nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM50432636(CHEMBL2347383 | US11407721, Example 10)
Affinity DataIC50: 86.6nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM50432643(CHEMBL2347392 | US11407721, Example 22)
Affinity DataIC50: 104nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562786(US11407721, Example 32 | US11407721, Example 33 | ...)
Affinity DataIC50: 150nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562786(US11407721, Example 32 | US11407721, Example 33 | ...)
Affinity DataIC50: 171nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562808(US11407721, Example 55 | (R)-2-((2S,3R,6S)-2,3-Bis...)
Affinity DataIC50: 179nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562807(US11407721, Example 54)
Affinity DataIC50: 196nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562786(US11407721, Example 32 | US11407721, Example 33 | ...)
Affinity DataIC50: 199nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM50432635(CHEMBL2347389 | US11407721, Example 21)
Affinity DataIC50: 217nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562777(US11407721, Example 23 | 2-((2S,5R,6S)-6-(3-Chloro...)
Affinity DataIC50: 233nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562799(US11407721, Example 46)
Affinity DataIC50: 259nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562806(US11407721, Example 53)
Affinity DataIC50: 276nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562805(US11407721, Example 52)
Affinity DataIC50: 279nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM50432643(CHEMBL2347392 | US11407721, Example 22)
Affinity DataIC50: 299nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562817(US11407721, Example 64 | (2S,5R,6S)-6-(3-Chlorophe...)
Affinity DataIC50: 322nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562818(US11407721, Example 65 | 2-((2S,5R,6S)-4-((R)-1-Am...)
Affinity DataIC50: 361nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562810(US11407721, Example 57 | (R)-2-((2S,3R,6S)-2,3-Bis...)
Affinity DataIC50: 391nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562800(US11407721, Example 47)
Affinity DataIC50: 400nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562789(US11407721, Example 35 | 4-(((2S,5R,6S)-4-((R)-1-(...)
Affinity DataIC50: 403nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM50432643(CHEMBL2347392 | US11407721, Example 22)
Affinity DataIC50: 408nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562801(US11407721, Example 48)
Affinity DataIC50: 420nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562820(US11407721, Example 67 | 2-((2S,5R,6S)-4-((R)-1-(1...)
Affinity DataIC50: 425nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562820(US11407721, Example 67 | 2-((2S,5R,6S)-4-((R)-1-(1...)
Affinity DataIC50: 426nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM50432636(CHEMBL2347383 | US11407721, Example 10)
Affinity DataIC50: 434nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562809(US11407721, Example 56 | (R)-2-((2S,3R,6S)-2,3-Bis...)
Affinity DataIC50: 453nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562798(US11407721, Example 45 | (R)-2-((2S,3R,6S)-2,3-Bis...)
Affinity DataIC50: 466nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562826(US11407721, Example 73 | (5R,6S)-6-(3-Chlorophenyl...)
Affinity DataIC50: 466nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562789(US11407721, Example 35 | 4-(((2S,5R,6S)-4-((R)-1-(...)
Affinity DataIC50: 473nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562788(US11407721, Example 34 | (R)—N-(2-Amino-2-oxo...)
Affinity DataIC50: 486nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562821(US11407721, Example 68 | 2-((2S,5R,6S)-6-(3-Chloro...)
Affinity DataIC50: 488nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562778(US11407721, Example 24 | (2S,5R,6S)-6-(3-Chlorophe...)
Affinity DataIC50: 492nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562790(US11407721, Example 36 | (2S,5R,6S)-4-((R)-1-(1H-T...)
Affinity DataIC50: 514nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562782(US11407721, Example 28 | 1-((R)-2-((2S,3R,6S)-2,3-...)
Affinity DataIC50: 524nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562795(US11407721, Example 42 | (S)-2-((2R,3S,6R)-2,3-Bis...)
Affinity DataIC50: 539nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562824(US11407721, Example 71 | (S)-2-((2S,3R,6S)-2,3-Bis...)
Affinity DataIC50: 544nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM50432636(CHEMBL2347383 | US11407721, Example 10)
Affinity DataIC50: 557nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562802(US11407721, Example 49)
Affinity DataIC50: 561nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562783(US11407721, Example 29 | (R)-2-((2S,3R,6S)-2-(4-Ch...)
Affinity DataIC50: 565nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562803(US11407721, Example 50 | (R)-2-((2S,3R,6S)-2,3-Bis...)
Affinity DataIC50: 568nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562780(US11407721, Example 26 | 2-((2S,5R,6S)-4-Benzyl-6-...)
Affinity DataIC50: 591nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562831(US11407721, Example 78 | 2-((2S,5R,6S)-6-(3-Chloro...)
Affinity DataIC50: 611nMAssay Description:The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562822(US11407721, Example 69 | 2-((2S,5R,6S)-6-(3-Chloro...)
Affinity DataIC50: 617nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562821(US11407721, Example 68 | 2-((2S,5R,6S)-6-(3-Chloro...)
Affinity DataIC50: 659nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562804(US11407721, Example 51)
Affinity DataIC50: 676nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562784(US11407721, Example 30 | (R)-2-((2S,3R,6S)-2-(4-Ch...)
Affinity DataIC50: 677nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562819(US11407721, Example 66 | 2-((2S,5R,6S)-6-(3-Chloro...)
Affinity DataIC50: 697nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562790(US11407721, Example 36 | (2S,5R,6S)-4-((R)-1-(1H-T...)
Affinity DataIC50: 712nMAssay Description:As the potencies of the HDM2 inhibitors increased, an improved HTRF assay (HTRF2 assay) was developed. All assay conditions remained the same as desc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562819(US11407721, Example 66 | 2-((2S,5R,6S)-6-(3-Chloro...)
Affinity DataIC50: 718nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM562784(US11407721, Example 30 | (R)-2-((2S,3R,6S)-2-(4-Ch...)
Affinity DataIC50: 726nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase Mdm2 [1-188](Human)
Amgen

US Patent
LigandPNGBDBM50432643(CHEMBL2347392 | US11407721, Example 22)
Affinity DataIC50: 738nMAssay Description:This assay was run using the same conditions as the HTRF1 assay except that 20 uL of GST-hMDM2 was incubated with 1.0 ul of diluted compound.More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 151 total ) | Next | Last >>
Jump to: